Skip to content
Search

Latest Stories

Breast Cancer survivors face heightened risk of second cancers, new research reveals

Breast Cancer survivors face heightened risk of second cancers, new research reveals
Higher risks of breast cancer and second primary cancers for individuals residing in areas of greater socioeconomic deprivation 

A groundbreaking study analysing data from nearly 600,000 cancer patients in England has shed light on the increased risk of second cancers among breast cancer survivors.

The research conducted by University of Cambridge in association with the Lancet Regional Health-Europe studied data from over 580,000 female and over 3,500 male breast cancer survivors diagnosed between 1995 and 2019 using the National Cancer Registration Dataset.


The findings suggest that survivors of breast cancer, the most prevalent cancer in the UK, face a substantially higher risk of developing second primary cancers.

According to the research, female survivors exhibited a twofold increase in the risk of contralateral breast cancer compared to the general population.

The data highlighted an 87 per cent greater risk of endometrial cancer, a 58 per cent greater risk of myeloid leukemia, and a 25 per cent  greater risk of ovarian cancer in female survivors.

Additionally, male breast cancer survivors were found to be 55 times more likely to develop contralateral breast cancer and 58  per cent more likely to develop prostate cancer than the general male population.

The risk was found to be particularly elevated in individuals residing in areas of greater socioeconomic deprivation facing a 35 per cent greater risk of second primary cancers.

The study also factored the age of patients during their first diagnosis, with younger survivors facing a substantially higher risk of developing second primary cancers compared to their older counterparts.

Isaac Allen, a PhD student at Clare Hall, stressed the importance of addressing health inequalities, stating:

“We need to fully understand why they are at greater risk of second cancers so that we can intervene and reduce this risk.”

Furthermore, researchers emphasised the need for further investigation to understand the underlying factors driving these differences and to develop strategies to tackle health inequalities.

The research, funded by Cancer Research UK with support from the National Institute for Health and Care Research Cambridge Biomedical Research Centre, underscores the importance of robust data sets in advancing our understanding of cancer risks and outcomes.

Katrina Brown, senior cancer intelligence manager at Cancer Research UK, highlighted the significance of the study, stating, “More research is needed to understand what is driving this difference and how to tackle these health inequalities.”

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less